500mg Fulvestrant in HR+ MBC

Fudan University

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT03708432

YOUNGBC-4

Details and patient eligibility

About

To study the real world use of 500mg Fulvestrant in HR+ MBC.

Full description

An observational, retrospective study of 500mg Fulvestrant in hormone receptor+/HER2- advanced breast cancer

Enrollment: 100 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosed with ER/PR+，HER2- advanced breast cancer
2. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.

3.500mg Fulvestrant treatment of advanced breast cancer for at least one month, between Jan 2011 and Dec 2015.

4.Available medical history

Exclusion criteria

1. Incomplete medical history
2. HER2 overexpression or gene amplification, ie, immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+, where appropriate.

Trial design

100 participants in 1 patient group

Fulvestrant

Description:

Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15